Sarcopenia during androgen-deprivation therapy for prostate cancer.

ABSTRACT:

Purpose

To characterize changes in lean body mass (LBM) in men with prostate cancer receiving androgen-deprivation therapy (ADT).

Patients and methods

We prospectively evaluated LBM in a prespecified substudy of a randomized controlled trial of denosumab to prevent fractures in men receiving ADT for nonmetastatic prostate cancer. LBM was measured by total-body dual-energy x-ray absorptiometry at study baseline and at 12, 24, and 36 months. The analyses included 252 patients (132, denosumab; 120, placebo) with a baseline and at least one on-study LBM assessment. Patients were stratified by age (< 70 v ≥ 70 years) and by ADT duration (≤ 6 v > 6 months).

Results

Median ADT duration was 20.4 months at study baseline. Mean LBM decreased significantly from baseline, by 1.0%

SUBMITTER: Smith MR 

PROVIDER: S-EPMC3434987 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature